172 related articles for article (PubMed ID: 37999116)
21. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
22. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Passero FC; Grapsa D; Syrigos KN; Saif MW
Expert Rev Anticancer Ther; 2016 Jul; 16(7):697-703. PubMed ID: 27219482
[TBL] [Abstract][Full Text] [Related]
23. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
24. Predicting the chemosensitivity of pancreatic cancer cells as a personalized therapy.
Rudno-Rudzińska J; Michel O; Płochocki M; Kulbacka J
Adv Clin Exp Med; 2022 Sep; 31(9):1049-1053. PubMed ID: 36135813
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan (Campto) in the treatment of pancreatic cancer.
Pizzolato JF; Saltz LB
Expert Rev Anticancer Ther; 2003 Oct; 3(5):587-93. PubMed ID: 14599083
[TBL] [Abstract][Full Text] [Related]
26. Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients.
He M; Sun J; Zhao D; He H; Wang B; Xu L; Shang Y; Ren S; Zhang Y; Wu T
Int J Hyperthermia; 2019; 36(1):394-402. PubMed ID: 30917701
[TBL] [Abstract][Full Text] [Related]
27. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Frampton JE
Drugs; 2020 Jul; 80(10):1007-1018. PubMed ID: 32557396
[TBL] [Abstract][Full Text] [Related]
28. Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.
Yokoi E; Mabuchi S; Shimura K; Komura N; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Invest New Drugs; 2019 Oct; 37(5):818-827. PubMed ID: 30374654
[TBL] [Abstract][Full Text] [Related]
29. Selecting chemotherapy for pancreatic cancer: Far away or so close?
Shi S; Yu X
Semin Oncol; 2019 Feb; 46(1):39-47. PubMed ID: 30611527
[TBL] [Abstract][Full Text] [Related]
30. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
31. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.
Vidal A; Muñoz C; Guillén MJ; Moretó J; Puertas S; Martínez-Iniesta M; Figueras A; Padullés L; García-Rodriguez FJ; Berdiel-Acer M; Pujana MA; Salazar R; Gil-Martin M; Martí L; Ponce J; Molleví DG; Capella G; Condom E; Viñals F; Huertas D; Cuevas C; Esteller M; Avilés P; Villanueva A
Clin Cancer Res; 2012 Oct; 18(19):5399-411. PubMed ID: 22896654
[TBL] [Abstract][Full Text] [Related]
32. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
33. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Petrelli F; Parisi A; Tomasello G; Mini E; Arru M; Russo A; Garrone O; Khakoo S; Ardito R; Ghidini M
BMC Gastroenterol; 2023 Jun; 23(1):212. PubMed ID: 37337148
[TBL] [Abstract][Full Text] [Related]
35. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy.
Hofmann C; Buttenschoen K; Straeter J; Henne-Bruns D; Kornmann M
Anticancer Res; 2005; 25(2A):795-804. PubMed ID: 15868911
[TBL] [Abstract][Full Text] [Related]
36. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Ko AH
Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma.
Anobile DP; Bironzo P; Picca F; Lingua MF; Morena D; Righi L; Napoli F; Papotti MG; Pittaro A; Di Nicolantonio F; Gigliotti C; Bussolino F; Comunanza V; Guerrera F; Sandri A; Leo F; Libener R; Aviles P; Novello S; Taulli R; Scagliotti GV; Riganti C
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34066159
[TBL] [Abstract][Full Text] [Related]
38. Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Milano G; Innocenti F; Minami H
Cancer Sci; 2022 Jul; 113(7):2224-2231. PubMed ID: 35445479
[TBL] [Abstract][Full Text] [Related]
39. Second-line treatment for metastatic pancreatic cancer.
Paluri RK; Kasi A; Young C; Posey JA
Clin Adv Hematol Oncol; 2020 Feb; 18(2):106-115. PubMed ID: 32558804
[TBL] [Abstract][Full Text] [Related]
40. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
